ISR’s report provides a thorough analysis of Forest Laboratories’ R&D pipeline, clinical trial activity, patents, FDA submissions, and includes profiles of Forest’s key products. How You Can Use This Report: Pharmaceutical Companies: Identify the clinical and commercial status of competing compounds and understand how these will affect the launch of similar products. Service Providers: Learn Forest’s strategic direction and better understand their clinical development pipeline. For the full report preview, with table of contents, additional sample pages, and ordering information, please visit our website: http://www.isrreports.com/product/forest-labs-clinical-development-profile/

1. EW
PR
EV
I
Forest Labs Clinical
Development Profile
Info@ISRreports.com
©2014 Industry Standard Research
www.ISRreports.com

2. act with confidence
Report Overview
ISR’s report provides a thorough analysis of Forest Laboratories’ R&D pipeline, clinical trial activity, patents,
FDA submissions, and includes profiles of Forest’s key products.
Methodologies:
Data have been compiled through an exhaustive secondary research effort. ISR has utilized company
websites, annual reports, clinicaltrials.gov, and government filings along with additional sources to provide
clinical trial and key product data.
44
Charts and Graphs
Q1,
2014
Publication Date
50
Pages
Report Structure:
1. Background and Strategy
2. Financial Condition
• Drug sales
• Stock performance
•
•
•
•
3. R&D Pipeline Overview
•
•
•
•
•
•
4. Clinical Trial Activity (segmented by
phase and trial type)
Anti-infective
Cardiovascular
CNS
Gastrointestinal
Pain Management
Respiratory
Number of clinical trials
Length of clinical trials
Projected vs. Actual on-going trial length
Enrollment in clinical trials
5. Patents
6. FDA Submissions
• Approved drugs
• Discontinued drugs
7. Key Product Profiles
What you will learn in this report:
• Drug sales and company financial condition
over the past four years
• Number, length, and patient enrollment of
clinical trials segmented by phase and trial type
• Current R&D pipeline overview
• Important aspects of Forest’s key products such
as MOA, dosing, and interaction characteristics
How you can use this report:
• Pharmaceutical Companies: Identify the
clinical and commercial status of competing
compounds and understand how these will
affect the launch of similar products.
• For Service Providers: Learn Forest’s strategic
direction and better understand their clinical
development pipeline.
NEXT: Table of Contents and Sample Pages
www.ISRreports.com ©2014 | Preview of: Forest Labs Clinical Development Profile
2

3. act with confidence
Table of Contents
For table of contents and additional sample pages, download the full preview,
available on our website:
www.isrreports.com/product/forest-labs-clinical-development-profile/
www.ISRreports.com ©2014 | Preview of: Forest Labs Clinical Development Profile
3

4. act with confidence
Sample Page
Clinical trial activity
act with confidence
Clinical trial activity
Data used in this analysis was pulled from ClinicalTrials�gov (www�clinicaltrials�gov) on
10 December 2013� The analysis includes all trials conducted by Forest Laboratories
listed on ClinicalTrials�gov�
Data/ clinical trials were segmented into three groups:
• Ongoing trials (N=51 trials)—these clinical studies are currently ongoing�
• Past 2 years (N=84 trials)—these trials were completed in the past two years�
• Historic trials (N=141 trials)—these trials were completed more than two years ago
Clinical trial activity
and were not analyzed for this report�
Clinical trial activity
The analyses that follow center on only the 135 clinical trials that are currently ongoing
and those that have been completed in the past two years�
act with confidence
For definitional purposes:
act with confidence
• An “ongoing” trial is a trial with an ending date after 1 December 2013�
• A “recently completed” trial is one with an ending date occurring after 1 December
2011 but before 1 December 2013 (past two years)�
The following sections reflect the number of clinical trials that were found in the
clinical trials database�
The following sections reflect the number of clinical trials that were found in the
clinical trials database�
Number of clinical trials, by phase
Percentages are based on the number of ongoing and
Number of clinical trials, (N=135)� recently read the table: 2%two
by phase completed (past of
years) trials conducted by Forest Laboratories
How to
the 51 ongoing based on the number of Laboratories are in Phase 1�
Percentages aretrials conducted by Forestongoing and recently completed (past two
years) trials conducted by Forest Laboratories (N=135)� How to read the table: 2% of
the 51 ongoing trials conducted by Forest Laboratories are in Phase 1�
Ongoing
Recently
Total
Completed Trials
Ongoing
Total
Phase 1
Total 2
Phase
Phase 1
Phase 3
Phase 2
Phase 4
Phase 3
No Phase
Phase 4
No Phase
51
1 (2%)
51
9 (18%)
1 (2%)
15 (29%)
9 (37%)
19(18%)
15 (14%)
7 (29%)
19 (37%)
7 (14%)
(past two years)
Recently
Completed Trials
84
(past two years)
3 (4%)
17 84
(20%)
3 (32%)
27 (4%)
17 (20%)
26 (31%)
27 (13%)
11 (32%)
26 (31%)
11 (13%)
Total
135
4 (3%)
26135
(19%)
4 (31%)
42 (3%)
26 (19%)
45 (33%)
42 (13%)
18 (31%)
45 (33%) Research
© 2014 Industry Standard
18 (13%)
www.ISRreports.com ©2014 | Forest Labs Clinical Development Profile
© 2014 Industry Standard Research
14
Study type distribution (e�g� interventional) Development Profile
www.ISRreports.com ©2014 | Preview of: Forest Labs Clinical
This is an enterprise-wide license and this file is not to be distributed beyond the terms of this agreement. For information on the license holder, please contact ISR (info@ISRreports.com).
The table
the number of ongoing and recently completed
StudyrepresentsForest Laboratories by the type of study type listed(past two years)
type distribution (e�g� interventional)
trials conducted by
in
4

5. act with confidence
Sample Page: Key Product Profiles
For table of contents and additional sample pages, download the full preview,
available on our website:
www.isrreports.com/product/forest-labs-clinical-development-profile/
www.ISRreports.com ©2014 | Preview of: Forest Labs Clinical Development Profile
5

6. act with confidence
Ordering Information
For pricing and ordering information, please visit our website:
www.isrreports.com/product/forest-labs-clinical-development-profile/
Save on this,
or any ISR
report, by
registering a
free account
Register now
• Receive a $250 instant credit towards any ISR report
• Earn 10% credit towards all future purchases
• Receive advanced notifications on ISR’s latest reports and free resources
About Industry Standard Research
Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.
For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www.
ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports.
www.ISRreports.com ©2014 | Preview of: Forest Labs Clinical Development Profile
6

7. The ISR Difference
act with confidence
Custom-quality syndicated market research
www.ISRreports.com
ISR's Reports
vs.
The Common
Syndicated Report
How confident are you?
Research methods
Mostly primary
research;
always appropriate
for the topic
vs.
vs.
One size fits all;
usually publically
available data
Data Collection
ISR's proprietary data collection
tools and channels support fast,
high quality data collection
vs.
Struggle to recruit the right
targets and enough of them
Respondents
Sophisticated screening
ensures genuine
decision-makers
vs.
Undisclosed
methodologies and
respondent demographics
Sample Sizes
Robust sample sizes that
instill confidence
vs.
Often insufficient industry
representation that leaves you
defending results
Analysts
Decades of experience
means more insights that are
immediately usable
vs.
vs.
Junior analysts capable of
reporting numbers
www.ISRreports.com ©2013 | | ©2014 | Preview of: Forest Labs Industry’s HEOR Functions
www.ISRreports.com Preview of: Benchmarking European Industry’s HEOR Functions 7
www.ISRreports.com ©2013©2014 Preview of: BenchmarkingPharmaClinical Development Profile 10
www.ISRreports.com | Preview of: Benchmarking the the Pharma Investigator Payments